Novel Insights about Synergistic Effect of Zamzam Water with SGL2 Inhibitors on Wound Healing in STZ-Induced Diabetic Rats: The Role of anti-Inflammatory and Proangiogenic Effects

J Invest Surg. 2023 Dec;36(1):2266736. doi: 10.1080/08941939.2023.2266736. Epub 2023 Oct 9.

Abstract

Background: Hyperglycemia usually impairs wound healing by dysregulating the inflammatory response and angiogenesis. This study aimed to examine the synergistic effect of dapagliflozin and Zamzam water (ZW) on the healing of diabetic wounds and to explore their anti-inflammatory and proangiogenic effects.Materials and methods: A full-thickness excisional wound was made on the backs of all groups after two weeks of diabetes induction. Forty rats were divided into five groups, with eight rats per group; Group 1: Control non-diabetic rats; Group II: Untreated diabetic rats; Group III: Diabetic rats drinking ZW; Group IV: Diabetic rats receiving an oral dose of 1 mg/kg dapagliflozin; and Group V: Received both dapagliflozin and ZW. The healing of diabetic wounds was assessed by measuring wound closure, oxidative stress markers, immunohistochemical staining of NF-βB, VEGF, CD34, CD45, Ki-67, and eNOS, gene expression of MMP-9, TGF-β1, EGF-b1, FGF, and Col1A1, protein levels of TNFα, IL-1β, IL6, Ang II, and HIF-1α by ELISA assay, and histological examination with H & E and Masson's trichrome. Combined treatment with dapagliflozin and ZW significantly (p < 0.05) enhanced the wound closure and antioxidant enzyme level, with apparent histological improvement, and shortened the inflammatory stage of the diabetic wound by decreasing the level of inflammatory markers NF-κB, TNF-α, IL-1β, IL6, and CD45. Therefore, it improved angiogenesis markers VEGF, CD34, eNOS, EGF-β1, FGF, Ang II, and HIF-1α, increasing Ki-67 cellular proliferation. Moreover, it enhanced the remodeling stage by increasing MMP-2, TGF-β1, and Col1A1 levels compared to diabetic rats.

Keywords: Diabetic wound; Zamzam water; angiogenesis; anti-inflammatory; dapagliflozin.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Diabetes Mellitus, Experimental* / complications
  • Diabetes Mellitus, Experimental* / drug therapy
  • Epidermal Growth Factor / pharmacology
  • Epidermal Growth Factor / therapeutic use
  • Interleukin-6
  • Ki-67 Antigen
  • Rats
  • Transforming Growth Factor beta1* / pharmacology
  • Transforming Growth Factor beta1* / therapeutic use
  • Tumor Necrosis Factor-alpha
  • Vascular Endothelial Growth Factor A / metabolism
  • Wound Healing

Substances

  • dapagliflozin
  • Transforming Growth Factor beta1
  • Vascular Endothelial Growth Factor A
  • Epidermal Growth Factor
  • Interleukin-6
  • Ki-67 Antigen
  • Anti-Inflammatory Agents
  • Tumor Necrosis Factor-alpha